Advanz has claimed a first with a European launch of a rival to Ipsen’s Somatuline, introducing its generic lanreotide in Germany under the name Mytolac.

As political tensions between the UK and EU mount over the Northern Ireland Protocol instigated as part of the pair’s Brexit agreement, the off-patent industry is growing increasingly concerned that regulatory uncertainty will put supply at risk.

Sorrento and Mabpharm have revealed plans to take their infliximab “biobetter” global, after China’s NMPA approved the product, which has an improved safety profile compared to Remicade.

Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.

At an IGBA panel discussion moderated by Generics Bulletin’s editor, three industry leaders representing Europe, India and the US debated the key issues facing the international off-patent sector today.

Teva has announced a major management reshuffle that will see North America commercial vice-president Brendan O’Grady leave the company for a new role outside the pharmaceutical industry. Revealing his replacement, Teva also unveiled further changes.